文献速递心脏核医学

11C-匹兹堡化合物B正电子发射断层显像/计算机断层显像用于转甲状腺素蛋白心脏淀粉样变性患者Tafamidis治疗监测的可行性

Feasibility of 11C-Pittsburgh compound B positron emission tomography/computed tomography for treatment monitoring with Tafamidis in a patient with transthyretin cardiac amyloidosis.
PubMed 文献 · J Nucl Cardiol · 2024-01-05

本文报告一例77岁野生型转甲状腺素蛋白心脏淀粉样变性(ATTR-CA)女性患者,接受Tafamidis治疗14个月后症状改善、NT-pro BNP降低,心脏MRI和PYP闪烁显像无显著变化且NaF累积增加,而PiB PET/CT显示淀粉样沉积减少,提示PiB PET/CT在评估Tafamidis疗效方面可能优于NaF PET/CT。

要点

  • 77岁女性野生型ATTR-CA患者接受Tafamidis治疗14个月后症状改善、NT-pro BNP降低。
  • 治疗后心脏MRI和PYP闪烁显像无显著变化,NaF PET/CT显示累积增加。
  • PiB PET/CT显示淀粉样沉积减少,提示其可能优于NaF PET/CT评估Tafamidis疗效。

核心结论

  • PiB PET/CT显示淀粉样沉积减少,提示其在评估ATTR-CA患者Tafamidis疗效方面可能优于NaF PET/CT。

研究设计与样本

  • 本文报告一例77岁女性野生型转甲状腺素蛋白心脏淀粉样变性(ATTR-CA)患者。

主要发现

  • 患者表现为呼吸困难、心律失常和NT-pro BNP升高,初始心脏MRI、PYP闪烁显像、PiB PET/CT和NaF PET/CT均显示心脏异常。
  • Tafamidis治疗14个月后,患者症状改善且NT-pro BNP降低。
  • 治疗后心脏MRI和PYP闪烁显像无显著变化,NaF PET/CT显示NaF累积增加,而PiB PET/CT显示淀粉样沉积减少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present a 77-year-old woman with wild-type ATTR cardiac amyloidosis (ATTR-CA) who presented with dyspnea, arrhythmia, and elevated NT-pro BNP. Initial imaging including cardiac MRI, PYP scintigraphy, PiB PET/CT and NaF PET/CT revealed cardiac abnormalities. Tafamidis treatment was initiated. After 14 months, symptomatic improvement and reduced NT-pro BNP were observed. Cardiac MRI and PYP scintigraphy showed no significant change and increased NaF accumulation, while PiB PET/CT showed decreased amyloid deposition, suggesting that it may be superior to NaF PET/CT in assessing the therapeutic effect of tafamidis in ATTR-CA.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Fujioka K, Norikane T, Takami Y, et al. Feasibility of 11C-Pittsburgh compound B positron emission tomography/computed tomography for treatment monitoring with Tafamidis in a patient with transthyretin cardiac amyloidosis. J Nucl Cardiol. 2024. PMID: 38185410. doi:10.1016/j.nuclcard.2024.101800

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。